Bioequivalence of Ferrinemia vs Venofer in Healthy Volunteers

Phase 1, randomised, open-label trial of Energavit in iron deficiency anemia (IDA) (2 arms), sponsored by AZAD Pharma AG. Primary endpoints: Peak Plasma Concentration of baseline corrected total serum iron and serum transferrin-bound iron at 30 hours and Area Under the Plasma Concentration versus Time Curve of baseline corrected total serum iron and serum transferrin-bound iron at 30 hours. Started Mar 2017; status: completed.